These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34250397)

  • 1. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
    Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
    Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
    Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
    Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
    Kotecha RR; Gedvilaite E; Ptashkin R; Knezevic A; Murray S; Johnson I; Shapnik N; Feldman DR; Carlo MI; Shah NJ; Dunigan M; Huberman K; Benayed R; Zehir A; Berger MF; Ladanyi M; Tsui DWY; Motzer RJ; Lee CH; Voss MH
    JCO Precis Oncol; 2022 Jul; 6():e2200012. PubMed ID: 35797508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
    Rose Brannon A; Jayakumaran G; Diosdado M; Patel J; Razumova A; Hu Y; Meng F; Haque M; Sadowska J; Murphy BJ; Baldi T; Johnson I; Ptashkin R; Hasan M; Srinivasan P; Rema AB; Rijo I; Agarunov A; Won H; Perera D; Brown DN; Samoila A; Jing X; Gedvilaite E; Yang JL; Stephens DP; Dix JM; DeGroat N; Nafa K; Syed A; Li A; Lebow ES; Bowman AS; Ferguson DC; Liu Y; Mata DA; Sharma R; Yang SR; Bale T; Benhamida JK; Chang JC; Dogan S; Hameed MR; Hechtman JF; Moung C; Ross DS; Vakiani E; Vanderbilt CM; Yao J; Razavi P; Smyth LM; Chandarlapaty S; Iyer G; Abida W; Harding JJ; Krantz B; O'Reilly E; Yu HA; Li BT; Rudin CM; Diaz L; Solit DB; Arcila ME; Ladanyi M; Loomis B; Tsui D; Berger MF; Zehir A; Benayed R
    Nat Commun; 2021 Jun; 12(1):3770. PubMed ID: 34145282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
    Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
    Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.
    Zhou C; Yuan Z; Ma W; Qi L; Mahavongtrakul A; Li Y; Li H; Gong J; Fan RR; Li J; Molmen M; Clark TA; Pavlick D; Frampton GM; Forcier B; Moore EH; Shelton DK; Cooke M; Ali SM; Miller VA; Gregg JP; Stephens PJ; Li T
    J Hematol Oncol; 2018 Nov; 11(1):129. PubMed ID: 30400986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.